Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies
Shravan Madireddi, So-Young Eun, Seung‐Woo Lee, et al.
The Journal of Experimental Medicine (2014) Vol. 211, Iss. 7, pp. 1433-1448
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney, Paul D. Rennert, Gordon J. Freeman
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 8, pp. 561-584
Closed Access | Times Cited: 1200
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H.C. Baumeister, Gordon J. Freeman, Glenn Dranoff, et al.
Annual Review of Immunology (2016) Vol. 34, Iss. 1, pp. 539-573
Closed Access | Times Cited: 835
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester, Miguel F. Sanmamed, Jun Wang, et al.
Blood (2017) Vol. 131, Iss. 1, pp. 49-57
Open Access | Times Cited: 422
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
Ri‐Yao Yang, Linlin Sun, Ching-Fei Li, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 418
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses
Lindsay K. Ward-Kavanagh, Wai Lin, John R. Šedý, et al.
Immunity (2016) Vol. 44, Iss. 5, pp. 1005-1019
Open Access | Times Cited: 389
Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance
Donnele Daley, Vishnu R. Mani, Navyatha Mohan, et al.
Nature Medicine (2017) Vol. 23, Iss. 5, pp. 556-567
Open Access | Times Cited: 307
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
Todd Bartkowiak, Michael A. Curran
Frontiers in Oncology (2015) Vol. 5
Open Access | Times Cited: 236
Galectins and Immune Responses—Just How Do They Do Those Things They Do?
Sandra Thiemann, Linda G. Baum
Annual Review of Immunology (2016) Vol. 34, Iss. 1, pp. 243-264
Closed Access | Times Cited: 218
Role of Galectins in Tumors and in Clinical Immunotherapy
Feng‐Cheng Chou, Heng-Yi Chen, Chih-Chi Kuo, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 2, pp. 430-430
Open Access | Times Cited: 203
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
Miguel F. Sanmamed, Fernando Pastor, Alfonso R. Sánchez-Paulete, et al.
Seminars in Oncology (2015) Vol. 42, Iss. 4, pp. 640-655
Closed Access | Times Cited: 182
Galectin-9 as a biomarker of disease severity
Preeti Moar, Ravi Tandon
Cellular Immunology (2021) Vol. 361, pp. 104287-104287
Closed Access | Times Cited: 108
The universe of galectin-binding partners and their functions in health and disease
María F. Troncoso, María T. Elola, Ada G. Blidner, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 12, pp. 105400-105400
Open Access | Times Cited: 45
4-1BB immunotherapy: advances and hurdles
Rohit Kumar Singh, Young Ho Kim, Sang-Jin Lee, et al.
Experimental & Molecular Medicine (2024) Vol. 56, Iss. 1, pp. 32-39
Open Access | Times Cited: 21
Not All Immune Checkpoints Are Created Equal
Annika De Sousa Linhares, Judith Leitner, Katharina Grabmeier‐Pfistershammer, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 134
Principles of antibody-mediated TNF receptor activation
Harald Wajant
Cell Death and Differentiation (2015) Vol. 22, Iss. 11, pp. 1727-1741
Open Access | Times Cited: 129
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
Sherman M. Chin, Christopher R. Kimberlin, Zygy Roe-Žurž, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 123
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Aitziber Buqué, Norma Bloy, Fernando Aranda, et al.
OncoImmunology (2015) Vol. 4, Iss. 4, pp. e1008814-e1008814
Open Access | Times Cited: 121
Deciphering CD137 (4‐1BB) signaling in T‐cell costimulation for translation into successful cancer immunotherapy
Alfonso R. Sánchez-Paulete, Sara Labiano, María E. Rodríguez-Ruiz, et al.
European Journal of Immunology (2016) Vol. 46, Iss. 3, pp. 513-522
Open Access | Times Cited: 118
Translating the ‘Sugar Code’ into Immune and Vascular Signaling Programs
Juan P. Cerliani, Ada G. Blidner, Marta A. Toscano, et al.
Trends in Biochemical Sciences (2016) Vol. 42, Iss. 4, pp. 255-273
Open Access | Times Cited: 107
Galectin-9: From cell biology to complex disease dynamics
Sebastian John, Rashmi Mishra
Journal of Biosciences (2016) Vol. 41, Iss. 3, pp. 507-534
Closed Access | Times Cited: 97
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
Juan M. Zapata, Gema Pérez-Chacón, Pablo Carr-Baena, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 97
The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy
Sashi Kandel, Pratik Adhikary, Guangfu Li, et al.
Cancer Letters (2021) Vol. 510, pp. 67-78
Open Access | Times Cited: 96
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy
Rachel O’Neill, Xuefang Cao
Advances in cancer research (2019), pp. 145-194
Open Access | Times Cited: 85
Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels
Adrian M. Seifert, Charlotte Reiche, Max Heiduk, et al.
Oncogene (2020) Vol. 39, Iss. 15, pp. 3102-3113
Open Access | Times Cited: 81
Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
Najmeh Bozorgmehr, Siavash Mashhouri, Eliana Perez Rosero, et al.
mBio (2021) Vol. 12, Iss. 3
Open Access | Times Cited: 78
Page 1 - Next Page

Scroll to top